Novel HER2-Directed Treatments in Advanced Gastric Carcinoma: AnotHER Paradigm Shift?

SIMPLE SUMMARY: More than ten years after the first publication of the results of the ToGA phase III trial, active research avenues are exploring the role of novel agents targeting human epidermal growth factor receptor 2 (HER2). Preliminary reports have highlighted promising activity for several th...

Descripción completa

Detalles Bibliográficos
Autores principales: Ricci, Angela Dalia, Rizzo, Alessandro, Rojas Llimpe, Fabiola Lorena, Di Fabio, Francesca, De Biase, Dario, Rihawi, Karim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036476/
https://www.ncbi.nlm.nih.gov/pubmed/33916206
http://dx.doi.org/10.3390/cancers13071664

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036476/
https://www.ncbi.nlm.nih.gov/pubmed/33916206
http://dx.doi.org/10.3390/cancers13071664

Ejemplares similares